| scholarly article | Q13442814 |
| P50 | author | Lawrence Yannuzzi | Q6504769 |
| K. Bailey Freund | Q61727780 | ||
| Richard F Spaide | Q63168644 | ||
| Jason S Slakter | Q123481792 | ||
| James M Klancnik | Q125215691 | ||
| Diana Iturralde | Q125215714 | ||
| P2093 | author name string | Catherine B Meyerle | |
| Michael J Cooney | |||
| Yale L Fisher | |||
| John A Sorenson | |||
| P433 | issue | 4 | |
| P921 | main subject | bevacizumab | Q413299 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 451-457 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Retina | Q15753094 |
| P1476 | title | Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation | |
| P478 | volume | 27 |
| Q46496860 | Anti-VEGF treatment for retinal angiomatous proliferation |
| Q37111338 | Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress |
| Q36922406 | Bimonthly half-dose ranibizumab in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case report |
| Q50478584 | Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation. |
| Q34574080 | Contributions to the treatment of atypical forms of age-related macular degeneration |
| Q37143111 | Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review. |
| Q50511227 | Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. |
| Q37577410 | Intravitreal bevacizumab: an analysis of the evidence |
| Q46031092 | Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). |
| Q46885835 | Intravitreal triamcinolone and bevacizumab combination therapy for refractory choroidal neovascularization with retinal angiomatous proliferation |
| Q33886005 | Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. |
| Q37498854 | Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? |
| Q35874689 | One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages |
| Q31092005 | One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation |
| Q46077796 | One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. |
| Q35872677 | Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). |
| Q36488800 | Periodontal disease in a patient receiving Bevacizumab: a case report |
| Q43294467 | Ranibizumab for retinal angiomatous proliferation |
| Q43164512 | Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration |
| Q36954403 | Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. |
| Q33808187 | Resveratrol inhibits pathologic retinal neovascularization in Vldlr(-/-) mice |
| Q37658305 | Retinal angiomatous proliferation or retinal anastomosis to the lesion |
| Q44998626 | Retinal angiomatous proliferation responds safely to a double dose (1.0 mg) of ranibizumab |
| Q43118124 | Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation |
| Q46131421 | Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments |
| Q86551292 | Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation |
| Q36929380 | Vascular endothelial growth factor in eye disease |
| Q37986462 | Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence |
| Q50498550 | Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation. |
| Q88556853 | [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation] |
| Q50549303 | [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy]. |
Search more.